ライフサイエンスコーパス: mercaptopurine

1 rapy comprising ATRA, oral methotrexate, and mercaptopurine.

2 eukemia (ALL) includes prednisone and oral 6-mercaptopurine.

3 dose, and all patients received daily oral 6-mercaptopurine.

4 mined the efficacy of dexamethasone and IV 6-mercaptopurine.

5 ectiveness of the immuno-suppressive agent 6-mercaptopurine.

6 S-methylation of thiopurine drugs such as 6-mercaptopurine.

7 rove on azathioprine but responded well to 6-mercaptopurine.

8 ys 1 to 5, and a regimen of methotrexate and mercaptopurine.

9 1.27 (95% CI, 0.48-3.39) for azathioprine/6-mercaptopurine.

10 treated with the thiopurines azathioprine or mercaptopurine.

11 ntenance with ATRA, oral methotrexate, and 6-mercaptopurine.

12 lone or in combination with methotrexate and mercaptopurine.

13 ts a decreased V max and increased K m for 6-mercaptopurine.

14 sms in TPMT, can cause severe toxicity after mercaptopurine.

15 travenous methotrexate (1 g/m(2)) with daily mercaptopurine.

16 e mice were pretreated with leflunomide or 6-mercaptopurine.

17 , 11), whereas 6-thio NHD(+) (nicotinamide 6-mercaptopurine 5'-dinucleotide, 17) generates a cyclic d

18 their respective substrates, azathioprine/6-mercaptopurine, 5-fluorouracil and sulindac.

19 Although the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) are well

20 first 16 months of continuation therapy with mercaptopurine (6-MP) and asparaginase (L-ASP).

21 he aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for th

22 The thiopurines azathioprine and 6-mercaptopurine (6-MP) are effective immune modulators an

23 Azathioprine (AZA) and 6-mercaptopurine (6-MP) are used in pediatric patients wit

24 Azathioprine and its metabolite 6-mercaptopurine (6-MP) are well established immunosuppres

25 kemia (ALL) are generally instructed to take mercaptopurine (6-MP) in the evening and without food or

26 Clinical experience suggests that 6-mercaptopurine (6-MP) is effective therapy for children

27 To evaluate potential toxicity of 6-mercaptopurine (6-MP), we reviewed the records of 485 pa

28 mong patients treated with azathioprine or 6-mercaptopurine (6-MP).

29 f immunomodulators [azathioprine (AZA), or 6-mercaptopurine (6-MP)] and newer biologic agents (inflix

30 6-Mercaptopurine, 6-thioguanine and dasatinib are three im

31 ed for the simultaneously determination of 6-mercaptopurine, 6-thioguanine and dasatinib for the firs

32 for the selective and precise analysis of 6-mercaptopurine, 6-thioguanine and dasatinib in pharmaceu

33 ata revealed that the electro-oxidation of 6-mercaptopurine, 6-thioguanine and dasatinib is facilitat

34 at pH 8.0, the oxidation peak currents for 6-mercaptopurine, 6-thioguanine and dasatinib were found t

35 Compared with 6-mercaptopurine, 6-thioguanine causes excess toxicity wit

36 bolites of three clinically useful agents (6-mercaptopurine, 6-thioguanine, and Abacavir) can inhibit

37 Variability in prescribed doses of 6-mercaptopurine (6MP) and lack of adherence to a 6MP trea

38 6-Mercaptopurine (6MP) and methotrexate are the backbone o

39 Adequate exposure to oral 6-mercaptopurine (6MP) during maintenance therapy for chil

40 maintenance phase that includes daily oral 6-mercaptopurine (6MP).

41 ned either 6-thioguanine (750 patients) or 6-mercaptopurine (748 patients) during interim maintenance

42 ntenance therapy regimen included daily oral mercaptopurine (75 mg/m2) and weekly oral methotrexate (

43 lecular mechanism(s) of cellular response to mercaptopurine, a widely used antileukemic agent, we ass

44 azathioprine were superior to azathioprine/6-mercaptopurine: adalimumab (OR, 2.9; 95% CrI, 1.6-5.1),

45 In contrast, pretreatment of mice with 6-mercaptopurine, an inhibitor of de novo purine synthesis

46 ohn's disease were randomly assigned: 128 to mercaptopurine and 112 to placebo.

47 conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL l

48 he MRP4 drug resistance profile extends to 6-mercaptopurine and 6-thioguanine, two anticancer purine

49 d in the metabolism of thiopurines such as 6-mercaptopurine and 6-thioguanine.

50 an syndrome, the activator of the prodrugs 6-mercaptopurine and allopurinol, and a target for antipar

51 -TP) medications, including 6-thioguanine, 6-mercaptopurine and azathioprine, commonly used for immun

52 he immunosuppressive agents, azathioprine, 6-mercaptopurine and cyclosporine A, are compatible with p

53 lguanine, 8-azaguanine, 6-thioguanine, and 6-mercaptopurine and do not recognize any of the PurP liga

54 y 24 weeks of continuation chemotherapy with mercaptopurine and methotrexate.

55 -year treatment period with the following: 6-mercaptopurine and metronidazole [6MP/met] (comparator),

56 te the extensive clinical use and study of 6-mercaptopurine and other purine analogues, the cellular

57 types of adverse events were similar in the mercaptopurine and placebo groups.

58 g some of the antiproliferative effects of 6-mercaptopurine and potentially implicate Nurr1 as a mole

59 on of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plaus

60 The active metabolite of mercaptopurine and thioguanine (TG), deoxythioguanosine

61 Mercaptopurine and thioguanine are anticancer and immuno

62 armacokinetic and pharmacodynamic studies of mercaptopurine and thioguanine were done in Tpmt(-/-), T

63 Mercaptopurine and thioguanine, two of the most widely u

64 of TPMT on activation versus inactivation of mercaptopurine and thioguanine, we used a retroviral gen

65 ryl compounds, including medications such as mercaptopurine and thioguanine.

66 g setons, antibiotics, and azathioprine or 6-mercaptopurine and, in many cases, infliximab.

67 etabolites revealed elevated 6-MMP (6-methyl mercaptopurine) and low 6-TGN (6-thioguanine nucleotide)

68 andard dose of thiopurine (azathioprine or 6-mercaptopurine), and patients homozygous for a variant r

69 vement of guanylate kinase in 6-thioguanine, mercaptopurine, and abasic guanosine analog (e.g., ganci

70 hiopurines including 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine are effective anticance

71 ine drugs, including 6-thioguanine ((S)G), 6-mercaptopurine, and azathioprine, are widely employed an

72 ptions for 5-aminosalicylates azathioprine/6-mercaptopurine, and corticosteroids were extracted from

73 sessed the pharmacokinetics of methotrexate, mercaptopurine, and erythrocyte thioguanine nucleotide l

74 ians in optimizing therapeutic response to 6-mercaptopurine, and in identifying individuals at increa

75 city during consolidation therapy containing mercaptopurine, and remained significant in a multivaria

76 It is derived from 6-mercaptopurine, and these two drugs are often used inter

77 izing thiopurine therapy (i.e. azathioprine, mercaptopurine, and thioguanine).

78 th doxorubicin, vincristine, corticosteroid, mercaptopurine, and weekly high-dose asparaginase; and c

79 tarabine/etoposide; high-dose methotrexate/6-mercaptopurine; and daunorubicin, vincristine, prednison

80 Thioguanine and mercaptopurine are prodrugs requiring conversion into th

81 Azathioprine and 6-mercaptopurine are the standard maintenance therapies fo

82 nd Arg221, the only polar amino acids near 6-mercaptopurine, are highlighted as possible participants

83 ceptor Nurr1, interestingly, we identified 6-mercaptopurine as a specific activator of this receptor.

84 d following treatment with 10 daily doses of mercaptopurine at 100 mg/kg/d (0%, 68%, and 100% 50-day

85 resolution and the chemotherapeutic agent 6-mercaptopurine at 2.6 A resolution have been determined,

86 web-based randomisation system to oral daily mercaptopurine at a dose of 1 mg/kg bodyweight rounded t

87 ictor of outcome, but a direct comparison of mercaptopurine AUC in the remission and relapsed patient

88 A Cox regression analysis showed that mercaptopurine AUC was a marginally significant (P =.043

89 Thiopurine drugs (i.e., thioguanine [TG], mercaptopurine, azathioprine) are commonly used for the

90 the S-methylation (that is, inactivation) of mercaptopurine, azathioprine, and thioguanine and exhibi

91 patients are treated with standard doses of mercaptopurine, azathioprine, or thioguanine.

92 ntial 6-methylmercaptopurine production on 6-mercaptopurine/azathioprine (odds ratio, 3.0; 95% CI, 1.

93 6-Mercaptopurine/azathioprine alone and the addition of 6-

94 rticosteroids alone, 52 patients receiving 6-mercaptopurine/azathioprine alone or with corticosteroid

95 who were receiving corticosteroids and/or 6-mercaptopurine/azathioprine before surgery compared with

96 bowel disease receive corticosteroids and 6-mercaptopurine/azathioprine during elective bowel surger

97 adjusted odds ratio for patients receiving 6-mercaptopurine/azathioprine for any and major infectious

98 ine/azathioprine alone and the addition of 6-mercaptopurine/azathioprine for patients receiving corti

99 6-mercaptopurine/azathioprine is effective in IBD patients

100 ents receiving neither corticosteroids nor 6-mercaptopurine/azathioprine.

101 t an active site loop becomes ordered upon 6-mercaptopurine binding.

102 acid decreases V max and increases K m for 6-mercaptopurine but not K m for S-adenosyl- l-methionine.

103 xic effects of thiopurine prodrugs such as 6-mercaptopurine by methylating them in a reaction using S

104 We investigated whether mercaptopurine can prevent or delay postoperative clinic

105 ssant and anticancer drugs azathioprine or 6-mercaptopurine contains 6-thioguanine (6-TG).

106 We conclude that methylation of mercaptopurine contributes to the antiproliferative prop

107 regimens containing either oral (PO) MTX, PO mercaptopurine, dexamethasone, and vincristine or IV MTX

108 The effect of mercaptopurine did not significantly differ from placebo

109 to 10 pmol/g Hgb) and did not correlate with mercaptopurine dose or AUC.

110 undred ninety-one methotrexate doses and 190 mercaptopurine doses were monitored in 89 patients.

111 assignment was for daily oral or weekly IV 6-mercaptopurine during consolidation.

112 nosalicylate drugs as well as azothiaprine/6-mercaptopurine during pregnancy.

113 teroids and/or cyclosporine, azathioprine, 6-mercaptopurine, FK-506, methotrexate) were identified an

114 n therapy with the same combinations, plus 6-mercaptopurine, for 12 months total treatment.

115 fter in vivo treatment with methotrexate and mercaptopurine given alone or in combination.

116 p analysis, three (10%) of 29 smokers in the mercaptopurine group and 12 (46%) of 26 in the placebo g

117 pared with 13 (13%) of 99 non-smokers in the mercaptopurine group and 14 (16%) of 86 in the placebo g

118 16 (13%) of patients in the mercaptopurine group versus 26 (23%) patients in the pla

119 treatment in 39 (30%) of 128 patients in the mercaptopurine group versus 41 (37%) of 112 in the place

120 topurine; however, patients assigned to IV 6-mercaptopurine had decreased survival after relapse.

121 6-mercaptopurine has been a standard component of long-ter

122 The thiopurines azathioprine and 6-mercaptopurine have been extensively prescribed as immun

123 EFS was similar with oral or IV 6-mercaptopurine; however, patients assigned to IV 6-merca

124 ylates and 24.6% discontinued azathioprine/6-mercaptopurine in early pregnancy.

125 eport our experience with azathioprine and 6-mercaptopurine in patients with microscopic colitis.

126 potential benefit from the earlier use of 6-mercaptopurine in T-ALL therapy or the development of ad

127 = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab, ve

128 In addition, 6-mercaptopurine is a clinically important pro-drug that i

129 Mercaptopurine is an essential component of continuation

130 oietic toxicity in vivo after treatment with mercaptopurine is attenuated but not abolished by MSH2 d

131 Mercaptopurine is effective in preventing postoperative

132 es of the human polymorphism; indicates that mercaptopurine is more affected by the TPMT polymorphism

133 The purine anti-metabolite 6-mercaptopurine is one of the most widely used drugs for

134 nosuppressant thiopurines, azathioprine or 6-mercaptopurine, is associated with acute skin sensitivit

135 (TPMT) are known to have a marked effect on mercaptopurine metabolism and toxicity; however, some pa

136 rine methyl transferase and measurement of 6-mercaptopurine metabolites appear to be valuable for man

137 Studies of azathioprine and 6-mercaptopurine metabolites will make it easier and safer

138 f vincristine, adriamycin, prednisone, and 6-mercaptopurine (MP) and after continuous infusion of hig

139 ubstitution of oral 6-thioguanine (TG) for 6-mercaptopurine (MP) and triple intrathecal therapy (ITT)

140 Methotrexate (MTX) and mercaptopurine (MP) are widely used antileukemic agents

141 uorouracil, cytosine arabinoside (araC), and mercaptopurine (MP) demonstrated that Hmgb1(-/-) mouse e

142 Systemic exposure to mercaptopurine (MP) is critical for durable remissions i

143 Mercaptopurine (MP) is the mainstay of curative therapy

144 widely used antileukemic agent, we assessed mercaptopurine (MP) sensitivity in mismatch repair (MMR)

145 After mercaptopurine (MP) treatment (30 mg/kg/day for 14 days)

146 Thiopurines, including mercaptopurine (MP), 6-thioguanine ((S)G) and azathiopri

147 osed ALL after intravenous administration of mercaptopurine (MP).

148 ed with the combination of methotrexate plus mercaptopurine (MTX + MP).

149 -cell ALL included 2 years of treatment with mercaptopurine, MTX, vincristine, and prednisone (POMP).

150 Recent studies of azathioprine/6-mercaptopurine, nitroimidazole antibiotics, and inflixim

151 captopurine nucleotides from thioguanine and mercaptopurine nucleotides, respectively.

152 ower risk of isolated CNS relapse than did 6-mercaptopurine (odds ratio [OR] 0.53, 95% CI 0.30-0.92,

153 otrexate of at least 25 mg/m(2) per week and mercaptopurine of at least 75 mg/m(2) per day.

154 s in the azathioprine group were switched to mercaptopurine or methotrexate therapy because of intole

155 rexate sodium (OR, 0.60; 95% CI, 0.29-1.22), mercaptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycoph

156 s (OR, 3.4; 95% CI, 1.8-6.2), azathioprine/6-mercaptopurine (OR, 3.1; 95% CI, 1.7-5.5), and inflixima

157 xposed to 5-aminosalicylates, azathioprine/6-mercaptopurine, or corticosteroids during their first tr

158 iffered among genotypes after treatment with mercaptopurine (P < 0.0001 and P = 0.044, respectively)

159 Methotrexate and mercaptopurine plasma concentrations and erythrocyte thi

160 from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.

161 rine regulation of Nurr1 demonstrates that 6-mercaptopurine regulates Nurr1 through a region in the a

162 A detailed analysis of 6-mercaptopurine regulation of Nurr1 demonstrates that 6-m

163 , was a substrate, and it was converted to 6-mercaptopurine ribonucleotide.

164 etabolites, thiouric acid (TU) and 2-amino-6-mercaptopurine riboside (6-TGR).

165 (p < 0.05) increased the S6-(4-nitrobenzyl)-mercaptopurine riboside (NBMPR) IC50 values by approxima

166 6-mercaptopurine should remain the thiopurine of choice fo

167 A metabolite of AZA, 6-mercaptopurine, still possessed this antiviral effect, b

168 contrast, TPMT+ cells were more sensitive to mercaptopurine than MOCK cells (IC(50) = 0.52 +/- 0.20 m

169 bo-controlled trial reported the efficacy of mercaptopurine therapy for children newly diagnosed with

170 nces the risk of GI toxicity associated with mercaptopurine therapy.

171 adenosyl- l-homocysteine and the substrate 6-mercaptopurine, to 1.8 and 2.0 A resolution, respectivel

172 identify additional genetic determinants of mercaptopurine toxicity, a genome-wide analysis was perf

173 with wild-type TPMT develop toxicity during mercaptopurine treatment for reasons that are not well u

174 econd DI; however, replacement of PO MTX, PO mercaptopurine, vincristine, and dexamethasone during IM

175 ars post-CR date, alternated three cycles of mercaptopurine, vincristine, methotrexate, and prednison

176 The higher sensitivity of TPMT+ cells to mercaptopurine was associated with higher concentrations

177 ce chemotherapy with oral methotrexate and 6-mercaptopurine was continued for 30 months.

178 used antileukemic agents (eg, methotrexate, mercaptopurine), we determined the rate of DNPS and the

179 that 6-thioguanine is more effective than 6-mercaptopurine, we compared the efficacy and toxicity of

180 xhibited a haploinsufficient phenotype after mercaptopurine, whereas haploinsufficiency was less prom

181 The prodrugs azathioprine and 6-mercaptopurine, which are well-established anticancer an

182 dnisone and for intravenous (IV) over oral 6-mercaptopurine, which remain to be validated.

183 ient response to the chemotherapeutic drug 6-mercaptopurine, with some model parameters being patient